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Hollands et al provide an important contribution to evidence on the potential impact of 
DNA-based disease risk information on health behaviours. Based on the findings of their 
systematic review and meta-analysis, the authors conclude that: “existing evidence does not 
support expectations that such interventions could play a major role in motivating 
behaviour change to improve population health (1).” However, we contend that this 
conclusion is premature. In particular, there has been limited population-based research 
using risk estimates based on multiple genomic variants, for a broad range of health 
behaviours, and lack of evaluation of whether the impact may be influenced by the 
presence of other risk factors. We also agree with other rapid responses (Hay and McBride, 
Janssens, Burton) that highlight other limitations of the previous studies and the need for 
more research to more fully assess the potential role of genomics in facilitating behaviour 
change. 
With regards to “population health”, few studies in the review were representative of the 
general population. Most of the studies were based on ‘high-risk’ groups and some studies 
were restricted to small population subgroups such as factory workers or university 
students. A number of differences in characteristics between ‘high-risk’ groups and the 
broader average-risk population have been observed, such as base rates of screening and 
other health habits, and awareness of genetic testing and genetic literacy (2). Such 
differences could mean that genomic risk information might impact the broader population 
differently, but to date, few studies examining the impact of DNA-based disease risk 
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information have been undertaken in populations not defined by a particular characteristic, 
such as being at higher risk of a particular condition.  
Many of the studies in this systematic review communicated disease risk estimates based on 
single or few genomic variants. Single-gene common variants underestimate the complexity 
of genomic contributions to common diseases, have little effect on personal risk and are 
likely to produce risk messages of low motivational potency (2,3). Furthermore, 
expectations for the role of DNA-based disease risk information in improving population 
health are arguably based on testing for multiple (as opposed to single or few) genomic 
variants.3 As technology is advancing, we are finding more genomic variants that contribute 
to common, complex diseases. In our field of melanoma prevention, common genomic 
variants have been found in at least 20 genes (4) and they make a strong contribution to 
melanoma risk prediction (5,6). We recently conducted a pilot randomised controlled trial in 
which we provided the public with personalised genomic risk as a combined risk estimate 
based on variants in 21 melanoma genes. Our results showed strong interest, feasibility and 
acceptability of giving such information to the public, and potential ‘clinically important’ 
improvements to prevention behaviours (manuscript submitted). However, a larger, 
adequately-powered study is required to fully assess the impact of this intervention.  
Only one study (Glanz et al, 2013)(7) in this review measured sun-related behaviours as a 
primary outcome. Despite only 73 people in the study, they found a standardised mean 
difference of 0.43 (95% CI -0.03 to 0.90, P=0.07), indicating a borderline-significant increase 
in sun protection for the intervention group compared to the control group. Another finding 
by Glanz et al, not reported in the review by Hollands et al, was a significant increase in the 
frequency of skin self-examinations (P=0.002), which is important for secondary prevention 
of melanoma. Hollands et al argue that “clear justification” is required to conduct additional 
large scale trials in this field. We submit that these moderate effect sizes represent 
justification “that efficacy of a clinically important degree is possible” and deserve further 
investigation in a larger study, and with a broader population since the people in this study 
had a family history of melanoma. Equally important is a wide-ranging and interdisciplinary 
discussion as to what a “clear justification” can and should comprise. 
In summary, we contend that in order to make firm conclusions about a role for DNA-based 
disease risk information to improve population health, we need more population-based 
research using risk estimates based on multiple genomic variants, and evaluation of 
whether the impact may be influenced by the presence of other risk factors. More research 
is also needed to assess whether the effect of genomic risk information might differ when 
used as a strategy for primary prevention (e.g. targeting health behaviours to reduce 
disease incidence) versus secondary prevention (e.g. targeting screening behaviours to 
improve early detection) of disease. These investigations should be accompanied by psycho-
social and ethical evaluations of the impact of this information, and deliberation over what 
criteria are appropriate to use as justifications for this kind of data.  
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